OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease

Urology

Volumn 83, Issue 1, 2014, Pages 22-27

  Anderson, Rodney U ^a   Orenberg, Elaine K ^a   Glowe, Patricia ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; LEVOFLOXACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

ADULT; AGED; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ARTICLE; BLADDER CONTRACTION; BLADDER PRESSURE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CYSTOMETRY; CYSTOSCOPY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; MICTURITION; MIDDLE AGED; NEUROGENIC BLADDER; OPEN STUDY; PARKINSON DISEASE; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; QUESTIONNAIRE; TOPICAL ANESTHESIA; URINE INCONTINENCE; UROFLOWMETRY; VERY ELDERLY;

AGED; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; OFFICE VISITS; PARKINSON DISEASE; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE;

EID: 84891273790     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.09.017     Document Type: Article

References (21)

1. U. Mehnert, J. Birzele, K. Reuter, and B. Schurch The effect of botulinum toxin type A on overactive bladder symptoms in patients with multiple sclerosis: a pilot study J Urol 184 2010 1011 1016
2. F. Cruz, S. Herschorn, and P. Aliotta et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial Eur Urol 60 2011 742 750
3. D. Ginsberg, A. Gousse, and V. Keppenne et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity J Urol 187 2012 2131 2139
4. A. Giannantoni, A. Rossi, and E. Mearini et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy J Urol 182 2009 1453 1457
5. H. Kulaksizoglu, and Y. Parman Use of botulinum toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson's disease Parkinsonism Relat Disorders 16 2010 531 534
6. A. Giannantoni, A. Conte, and S. Proietti et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder J Urol 186 2011 960 964
7. K. Terayama, R. Sakakibara, and A. Ogawa et al. Weak detrusor contractility correlates with motor disorders in Parkinson's disease Mov Disord 27 2012 1775 1780
8. C.G. Goetz, W. Poewe, and O. Rascol et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations Mov Disord 19 2004 1020 1028
9. C.J. Kelleher, L.D. Cardozo, V. Khullar, and S. Salvatore A new questionnaire to assess the quality of life of urinary incontinent women Br J Obstet Gynaecol 104 1997 1374 1379
10. P.R. Reese, A.M. Pleil, G.J. Okano, and C.J. Kelleher Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder Qual Life Res 12 2003 427 442
11. C.J. Fowler Update on the neurology of Parkinson's disease Neurourol Urodyn 26 2007 103 109
12. L. Campeau, R. Soler, and E. Andersson K Bladder dysfunction and Parkinsonism: current pathophysiological understanding and management strategies Curr Urol Rep 12 2011 396 403
13. L. Yeo, R. Singh, and M. Gundeti et al. Urinary tract dysfunction in Parkinson's disease: a review Int Urol Nephrol 44 2012 415 424
14. G. Karsenty, P. Denys, and G. Amarenco et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/ neurogenic overactive bladder: a systematic literature review Eur Urol 53 2008 275 287
15. A. Apostolidis, P. Dasgupta, and P. Denys et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report Eur Urol 55 2009 100 119
16. V.W. Nitti, R. Dmochowski, and S. Herschorn et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial J Urol 189 2013 2186 2193
17. B.L. Cohen, R. Rivera, P. Barboglio, and A. Gousse Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection J Urol 177 2007 1006 1010 [discussion: 1010]
18. A. Reitz, P. Denys, and C. Fermanian et al. Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity Eur Urol 52 2007 1729 1735
19. W.M. White, R.B. Pickens, R. Doggweiler, and F.A. Klein Short-term efficacy of botulinum toxin A for refractory overactive bladder in the elderly population J Urol 180 2008 2522 2526
20. D. Sussman, V. Patel, and G. Del Popolo et al. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity Neurourol Urodyn 32 2013 242 249
21. R.P. Manecksha, I.M. Cullen, and S. Ahmad et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity Eur Urol 61 2012 928 935